Tweaking PET scans could sharpen lung cancer detection

NCT ID NCT02738398

Completed Diagnosis Sponsor: Abramson Cancer Center at Penn Medicine Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether changing how FDG PET/CT scans are taken and processed can make them more accurate for staging lung cancer. Thirty adults with non-small cell lung cancer were enrolled. The goal was to see if better imaging could help doctors determine if cancer has spread to lymph nodes in the chest, without needing extra tests.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: FDG PET/CT scan (a type of imaging test)
What this could lead to: If successful, this could lead to more accurate lung cancer staging, helping doctors choose better treatments without needing extra invasive procedures.
What could go wrong: This is a small, completed study focused on imaging technique, not a new treatment. The results may not change current practice or apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER (NSCLC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER (NSCLC)

Contacts and locations

Locations

Abramson Cancer Center of the University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.